280 related articles for article (PubMed ID: 22126453)
1. Drug interactions with Bacillus anthracis topoisomerase IV: biochemical basis for quinolone action and resistance.
Aldred KJ; McPherson SA; Wang P; Kerns RJ; Graves DE; Turnbough CL; Osheroff N
Biochemistry; 2012 Jan; 51(1):370-81. PubMed ID: 22126453
[TBL] [Abstract][Full Text] [Related]
2. Overcoming target-mediated quinolone resistance in topoisomerase IV by introducing metal-ion-independent drug-enzyme interactions.
Aldred KJ; Schwanz HA; Li G; McPherson SA; Turnbough CL; Kerns RJ; Osheroff N
ACS Chem Biol; 2013 Dec; 8(12):2660-8. PubMed ID: 24047414
[TBL] [Abstract][Full Text] [Related]
3. Topoisomerase IV-quinolone interactions are mediated through a water-metal ion bridge: mechanistic basis of quinolone resistance.
Aldred KJ; McPherson SA; Turnbough CL; Kerns RJ; Osheroff N
Nucleic Acids Res; 2013 Apr; 41(8):4628-39. PubMed ID: 23460203
[TBL] [Abstract][Full Text] [Related]
4. Bacillus anthracis GrlAV96A topoisomerase IV, a quinolone resistance mutation that does not affect the water-metal ion bridge.
Aldred KJ; Breland EJ; McPherson SA; Turnbough CL; Kerns RJ; Osheroff N
Antimicrob Agents Chemother; 2014 Dec; 58(12):7182-7. PubMed ID: 25246407
[TBL] [Abstract][Full Text] [Related]
5. Interactions between Quinolones and Bacillus anthracis Gyrase and the Basis of Drug Resistance.
Ashley RE; Lindsey RH; McPherson SA; Turnbough CL; Kerns RJ; Osheroff N
Biochemistry; 2017 Aug; 56(32):4191-4200. PubMed ID: 28708938
[TBL] [Abstract][Full Text] [Related]
6. Activity of quinolone CP-115,955 against bacterial and human type II topoisomerases is mediated by different interactions.
Aldred KJ; Schwanz HA; Li G; Williamson BH; McPherson SA; Turnbough CL; Kerns RJ; Osheroff N
Biochemistry; 2015 Feb; 54(5):1278-86. PubMed ID: 25586498
[TBL] [Abstract][Full Text] [Related]
7. Probing the differential interactions of quinazolinedione PD 0305970 and quinolones with gyrase and topoisomerase IV.
Pan XS; Gould KA; Fisher LM
Antimicrob Agents Chemother; 2009 Sep; 53(9):3822-31. PubMed ID: 19564360
[TBL] [Abstract][Full Text] [Related]
8. Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones.
Yague G; Morris JE; Pan XS; Gould KA; Fisher LM
Antimicrob Agents Chemother; 2002 Feb; 46(2):413-9. PubMed ID: 11796351
[TBL] [Abstract][Full Text] [Related]
9. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
Gootz TD; Zaniewski RP; Haskell SL; Kaczmarek FS; Maurice AE
Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
[TBL] [Abstract][Full Text] [Related]
10. Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.
Cheng J; Thanassi JA; Thoma CL; Bradbury BJ; Deshpande M; Pucci MJ
Antimicrob Agents Chemother; 2007 Jul; 51(7):2445-53. PubMed ID: 17502409
[TBL] [Abstract][Full Text] [Related]
11. Action of quinolones against Staphylococcus aureus topoisomerase IV: basis for DNA cleavage enhancement.
Anderson VE; Zaniewski RP; Kaczmarek FS; Gootz TD; Osheroff N
Biochemistry; 2000 Mar; 39(10):2726-32. PubMed ID: 10704224
[TBL] [Abstract][Full Text] [Related]
12. Role of the Water-Metal Ion Bridge in Quinolone Interactions with
Carter HE; Wildman B; Schwanz HA; Kerns RJ; Aldred KJ
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769202
[TBL] [Abstract][Full Text] [Related]
13. Role of the water-metal ion bridge in mediating interactions between quinolones and Escherichia coli topoisomerase IV.
Aldred KJ; Breland EJ; Vlčková V; Strub MP; Neuman KC; Kerns RJ; Osheroff N
Biochemistry; 2014 Sep; 53(34):5558-67. PubMed ID: 25115926
[TBL] [Abstract][Full Text] [Related]
14. Bypassing fluoroquinolone resistance with quinazolinediones: studies of drug-gyrase-DNA complexes having implications for drug design.
Drlica K; Mustaev A; Towle TR; Luan G; Kerns RJ; Berger JM
ACS Chem Biol; 2014 Dec; 9(12):2895-904. PubMed ID: 25310082
[TBL] [Abstract][Full Text] [Related]
15. Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin.
Strahilevitz J; Hooper DC
Antimicrob Agents Chemother; 2005 May; 49(5):1949-56. PubMed ID: 15855518
[TBL] [Abstract][Full Text] [Related]
16. Quinolones inhibit DNA religation mediated by Staphylococcus aureus topoisomerase IV. Changes in drug mechanism across evolutionary boundaries.
Anderson VE; Zaniewski RP; Kaczmarek FS; Gootz TD; Osheroff N
J Biol Chem; 1999 Dec; 274(50):35927-32. PubMed ID: 10585479
[TBL] [Abstract][Full Text] [Related]
17. The Glu-84 of the ParC subunit plays critical roles in both topoisomerase IV-quinolone and topoisomerase IV-DNA interactions.
Hiasa H
Biochemistry; 2002 Oct; 41(39):11779-85. PubMed ID: 12269820
[TBL] [Abstract][Full Text] [Related]
18. Quinolone resistance mutations in Streptococcus pneumoniae GyrA and ParC proteins: mechanistic insights into quinolone action from enzymatic analysis, intracellular levels, and phenotypes of wild-type and mutant proteins.
Pan XS; Yague G; Fisher LM
Antimicrob Agents Chemother; 2001 Nov; 45(11):3140-7. PubMed ID: 11600369
[TBL] [Abstract][Full Text] [Related]
19. Alterations in the DNA topoisomerase IV grlA gene responsible for quinolone resistance in Staphylococcus aureus.
Yamagishi J; Kojima T; Oyamada Y; Fujimoto K; Hattori H; Nakamura S; Inoue M
Antimicrob Agents Chemother; 1996 May; 40(5):1157-63. PubMed ID: 8723458
[TBL] [Abstract][Full Text] [Related]
20. Replacement of ParC alpha4 helix with that of GyrA increases the stability and cytotoxicity of topoisomerase IV-quinolone-DNA ternary complexes.
Pfeiffer ES; Hiasa H
Antimicrob Agents Chemother; 2004 Feb; 48(2):608-11. PubMed ID: 14742217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
